RBC Capital analyst Conor McNamara lowered the firm’s price target on Hologic to $85 from $87 and keeps a Sector Perform rating on the shares after its Q3 results. The firm is “not convinced” that the company can generate 5%-7% growth targeted by the management over the long term. RBC adds that it prefers to remain on the sidelines pending more clarity on Hologic’s M&A strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOLX: